An approach of MS therapy can be initiated by targeting SPT regulation by selecting one or more from a group of miRNAs such as miR-376, miR-30, miR-128, miR-126, miR-7, and miR-9, as these miRNAs are involved in interfering with Cer synthesis [49]. The gene discussed is CBLN1; the disease is myeloid sarcoma.